|
Fri. 20.10 16:00
|
J. Haanen: How to build your own lab and research group in academia
|
Young Oncologist session
|
|
Fri. 20.10 16:15
|
W. Van Houdt: When can we cure patients with metastatic sarcoma?
|
Challenge your Expert
|
|
Sat. 21.10 09:05
|
P. Baas: Biomarker-selected therapy: Progress or delusion?
|
Special Symposium
|
|
Sat. 21.10 09:20
|
S. Einerhand: ICRA: efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1
|
Proffered Paper Session
|
|
Sat. 21.10 10:20
|
D. Van de Wal: Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) patients in the Netherlands: data from a cross-sectional multicenter study
|
Presentation #1914MO Mini Oral session
|
|
Sat 21.10 10:30
|
G. Sonke: How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice?
|
Special session
|
|
Sat. 21.10 15:35
|
C. Blank: How to personalise neoadjuvant immunotherapy
|
Educational session
|
|
Sat. 21.10 16:30
|
M. Chalabi: Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK)
|
Educational session
|
|
Sun. 22.10 10:15
|
J. Lijnsvelt: CN3 - Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies
|
EONS session
|
|
Sun. 22.10 15:05
|
M. Tesselaar: Perioperative considerations and management of localised disease
|
Special Symposium
|
|
Sun. 22.10 15:15
|
Y. Verschoor: Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study
|
Presentation # LBA31 Mini Oral session
|
|
Sun. 22.10 16:42
|
M. Van Der Heijden: Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial
|
Proffered Paper session
|
|
Sun. 22.10 19:15
|
W. Van Houdt: Multidisciplinary management of non-melanoma skin cancer: Surgical Perspective
|
Industry Satellite Symposium
|
|
Mon. 23.10 10:35
|
R. Beets-Tan: How to perform an accurate staging?
|
Multidisciplinary session
|
|
Mon. 23.10 10:45
|
J. Borgers: TC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma
|
Proffered Paper Session
|
|
Mon. 23.10 11:05
|
J. Jonkers: Understanding and overcoming resistance to PARP inhibitors: What is the way forward?
|
Multidisciplinary session
|
|
Mon. 23.10 15:05
|
L. Van De Poll-Franse: Quality of life in IO-treated long-term survivors
|
Special symposium
|
|
Mon. 23.10 15:35
|
W. Van Houdt: How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A medical oncologist’s perspective
|
Educational session
|
|
Mon. 23.10 16:35
|
S. Janssen: The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study
|
Presentation #1693MO Mini Oral Session
|
|
Mon. 23.10 16:40
|
S. Janssen: Socio-economic consequences among adolescent and young adult cancer patients: A European perspective
|
Presentation #1694MO Mini Oral session
|
|
Mon 23.10 17:30
|
J. Haanen: BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6- encoding CAR-T cell-Amplifying RNA Vaccine (CARVac)
|
Presentation #LBA35 Mini Oral session
|
en
English
